Division of Oncology, Center for Applied Medical Research, University of Navarra, Avda. Pio XII, 55 31008 Pamplona, Spain.
Haematologica. 2010 Feb;95(2):293-302. doi: 10.3324/haematol.2009.013318.
While leukemia-originating stem cells are critical in the initiation and maintenance of leukemias, the existence of similar cell populations that may generate B-cell lymphoma upon mutation remains uncertain. Here we propose that committed lymphoid progenitor/precursor cells with an active V-D-J recombination program are the initiating cells of follicular lymphoma and mantle cell lymphoma when targeted by immunoglobulin (IG)- gene translocations in the bone marrow. However, these pre-malignant lymphoma-initiating cells cannot drive complete malignant transformation, requiring additional cooperating mutations in specific stem-cell programs to be converted into the lymphoma-originating cells able to generate and sustain lymphoma development. Conversely, diffuse large B-cell lymphoma and sporadic Burkitt's lymphoma derive from B lymphocytes that acquire translocations through IG-hyper-mutation or class-switching errors within the germinal center. Although secondary reprogramming mutations are generally required, some cells such as centroblasts or memory B cells that have certain stem cell-like features, or lymphocytes with MYC rearrangements that deregulate self-renewal pathways, may bypass this need and directly function as the lymphoma-originating cells. An alternative model supports an aberrant epigenetic modification of gene sets as the first occurring hit, which either leads to retaining stem-cell features in hematopoietic stem or progenitor cells, or reprograms stemness into more committed lymphocytes, followed by secondary chromosomal translocations that eventually drive lymphoma development. Isolation and characterization of the cells that are at the origin of the different B-cell non-Hodgkin's lymphomas will provide critical insights into the disease pathogenesis and will represent a step towards the development of more effective therapies.
虽然白血病起源的干细胞在白血病的起始和维持中至关重要,但存在类似的细胞群体,这些细胞在发生突变时可能会产生 B 细胞淋巴瘤,这一点仍不确定。在这里,我们提出,当骨髓中的免疫球蛋白(IG)基因易位靶向具有活跃 V-D-J 重组程序的定向淋巴祖细胞/前体细胞时,它们是滤泡性淋巴瘤和套细胞淋巴瘤的起始细胞。然而,这些潜在的恶性淋巴瘤起始细胞不能驱动完全恶性转化,需要在特定的干细胞程序中发生额外的协同突变,才能转化为能够产生和维持淋巴瘤发展的淋巴瘤起始细胞。相反,弥漫性大 B 细胞淋巴瘤和散发性伯基特淋巴瘤来源于 B 淋巴细胞,这些 B 淋巴细胞通过 IG 超突变或生发中心内的类别转换获得易位。尽管通常需要二次重编程突变,但某些细胞,如中心母细胞或具有某些干细胞样特征的记忆 B 细胞,或具有 MYC 重排的淋巴细胞,这些重排会解除自我更新途径的调控,可能绕过这种需求,并直接作为淋巴瘤起始细胞发挥作用。另一种模型支持作为第一个发生的打击的基因集的异常表观遗传修饰,这要么导致造血干细胞或祖细胞保留干细胞特征,要么将干细胞重编程为更定向的淋巴细胞,然后是继发的染色体易位,最终驱动淋巴瘤的发展。分离和鉴定不同 B 细胞非霍奇金淋巴瘤起源的细胞将为疾病发病机制提供重要的见解,并将代表朝着开发更有效的治疗方法迈出的一步。